晚期食管癌患者应用紫杉醇联合替吉奥治疗的疗效及毒副作用分析

Analysis of the Efficacy and Toxicity of Paclitaxel in Patients with Advanced Esophageal Cancer Therapy Combined with Gio

目的分析晚期食管癌患者应用紫杉醇联合替吉奥治疗的疗效及毒副作用。方法选取自2012年3月~2013年1月期间,我科室收治的40例晚期食管癌患者进行研究分析。所有患者均采用静脉滴注3 h,予患者紫杉醇175 mg/m^2;替吉奥胶囊每天70 mg/m^2,分别在早晚餐后口服,连服14 d,每三周为1个周期。2个周期后对患者的疗效和毒副作用进行评价。结果在经过治疗之后,对比紫杉醇联合替吉奥治疗晚期食管癌初治和复治的疗效,初治的患者的有效率明显高于复治的患者（u=4.047 0,P=0.000 1）;初治的患者的疾病控制率明显高于复治的患者（u=3.584 2,P=0.000 3）;差异具有统计学意义（P〈0.05）;毒副反应主要是胃肠道反应和骨髓抑制,患者均能耐受。结论紫杉醇联合替吉奥治疗晚期食管癌疗效肯定,且毒副反应可以耐受。

Objective Analysis of the efficacy of paclitaxel in patients with advanced esophageal cancer therapy combined with Gio and side effects Methods Since March 2012 ~ January 2013 period, my department treated 40 patients with advanced esophageal cancer research and analysis. All patients were treated with intravenous infusion of 3 h, to patients with paclitaxel 175 mg / m^2; Gio capsules 70 mg daily / m^2, respectively, in the morning and evening postprandial oral, and even served 14 d, every three weeks for one cycle. After two cycles of the efficacy and toxicity of patients evaluated. Results After treatment, compared to paclitaxel and Gio initial treatment in patients with advanced esophageal cancer and efficacy of retreatment and untreated patients was significantly higher than in patients with retreatment（u = 4.047 0, P = 0.000 1）; novo the disease control rate was significantly higher in patients previously treated patients（u = 3.584 2, P = 0.000 3）; the difference was statistically significant（P〈0.05）; toxicity is mainly gastrointestinal reactions and bone marrow suppression, patients could tolerated. Conclusion Paclitaxel and Gio treatment of advanced esophageal cancer is effective and tolerable toxicity.